Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Journal of Magnetic Resonance Imaging : JMRI
|
April 12, 2002
The OptiMARK clinical development program: summary of safety data
Jeffrey J Brown, Rita M Kristy, Gary R Stevens, et al.
Drugs & Aging
|
July 30, 2020
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
Sender Herschorn, David Staskin, Carol R Schermer, et al.
European Urology
|
November 18, 2019
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)
Adrian Wagg, David Staskin, Eli Engel, et al.
Drugs in R&D
|
May 11, 2019
A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation
Janet Kim, Sam Wilson, Nasrullah A Undre, et al.
Pharmacoeconomics - Open
|
May 19, 2019
Use of Initial Noninvasive Cardiac Testing and Association with Downstream Healthcare Resource: A Retrospective Review of Resources Used Across a 12-Month Window for Probable Type I Myocardial Infarction Patients
Dana Villines, Wm Thomas Summerfelt, James R Spalding, et al.
The Journal of International Medical Research
|
May 19, 2022
Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States
Stephen R Kraus, Junlong Li, Rita M Kristy, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 31, 2023
Assessment of women's treatment preferences for vasomotor symptoms due to menopause
Aki Shiozawa, Rebecca C Thurston, Erin Cook, et al.
The International Journal of Cardiovascular Imaging
|
August 13, 2021
Clinical experience with regadenoson SPECT myocardial perfusion imaging: insights into patient characteristics, safety, and impact of results on clinical management
Karthikeyan Ananthasubramaniam, Matthew Saval, Meredith Van Harn, et al.
Advances in Therapy
|
June 22, 2019
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
Kevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
Lower Urinary Tract Symptoms
|
May 14, 2021
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
Kevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Journal of Magnetic Resonance Imaging : JMRI
|
April 12, 2002
The OptiMARK clinical development program: summary of safety data
Jeffrey J Brown, Rita M Kristy, Gary R Stevens, et al.
Drugs & Aging
|
July 30, 2020
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
Sender Herschorn, David Staskin, Carol R Schermer, et al.
European Urology
|
November 18, 2019
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)
Adrian Wagg, David Staskin, Eli Engel, et al.
Drugs in R&D
|
May 11, 2019
A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation
Janet Kim, Sam Wilson, Nasrullah A Undre, et al.
Pharmacoeconomics - Open
|
May 19, 2019
Use of Initial Noninvasive Cardiac Testing and Association with Downstream Healthcare Resource: A Retrospective Review of Resources Used Across a 12-Month Window for Probable Type I Myocardial Infarction Patients
Dana Villines, Wm Thomas Summerfelt, James R Spalding, et al.
The Journal of International Medical Research
|
May 19, 2022
Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States
Stephen R Kraus, Junlong Li, Rita M Kristy, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
August 31, 2023
Assessment of women's treatment preferences for vasomotor symptoms due to menopause
Aki Shiozawa, Rebecca C Thurston, Erin Cook, et al.
The International Journal of Cardiovascular Imaging
|
August 13, 2021
Clinical experience with regadenoson SPECT myocardial perfusion imaging: insights into patient characteristics, safety, and impact of results on clinical management
Karthikeyan Ananthasubramaniam, Matthew Saval, Meredith Van Harn, et al.
Advances in Therapy
|
June 22, 2019
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
Kevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
Lower Urinary Tract Symptoms
|
May 14, 2021
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
Kevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
Page
of 2